VOSOL
LOE ApproachingNDAOTICSOLUTION/DROPS
Approved
May 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOSOL is an otic solution approved in 1960 for topical ear treatment, representing a legacy small-molecule product with a well-established safety and efficacy profile. The exact mechanism of action and specific indications are not publicly detailed in current labeling databases, but otic solutions typically treat bacterial or fungal ear infections or inflammation.
LOE Approaching
As an aging NDA approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team likely operates in maintenance mode with limited commercial expansion headroom.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VOSOL offers stability in a proven, low-risk commercial environment but limited career acceleration or innovation exposure. This role suits professionals seeking execution-focused experience in mature brand management or operational excellence rather than pipeline advancement.
Brand ManagerField Sales Representative
Worked on VOSOL at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.